Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Agents that target telomerase and telomeres

E Raymond1, D Sun, S F Chen

  • 1Human Telomerase Research Group, Institute for Drug Development - Cancer Therapy and Research Center, 14960 Omicron Drive, San Antonio, TX 78245-3217, USA.

Current Opinion in Biotechnology
|December 1, 1996
PubMed
Summary

Telomeres, the protective caps on chromosomes, are maintained by telomerase. Targeting telomerase and telomeres offers a promising strategy for developing novel anticancer drugs by exploiting differences in their lengths and expression in cancer cells.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

Cancer chemotherapy and pharmacology·2014
Same author

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

European journal of cancer (Oxford, England : 1990)·2012

Area of Science:

  • Genetics
  • Molecular Biology
  • Oncology

Background:

  • Telomeres are protective guanine-rich DNA sequences at chromosome ends.
  • Telomeres prevent DNA degradation and aberrant recombination.
  • Telomere length and maintenance are regulated by the enzyme telomerase.

Purpose of the Study:

  • To explore telomerase and telomere structures as targets for new anticancer agents.
  • To investigate the biological effects of telomerase and telomere inhibitors.
  • To develop novel therapeutic strategies for cancer treatment.

Main Methods:

  • Formulation of new models for in vitro and in vivo studies.
  • Analysis of telomerase expression in tumor versus somatic cells.
  • Drug design targeting telomerase or telomere structures.

Related Experiment Videos

Main Results:

  • Telomerase is expressed in tumor cells, which often have shorter telomeres.
  • Most somatic cells lack telomerase expression and maintain longer telomeres.
  • This differential expression highlights telomerase and telomeres as viable drug targets.

Conclusions:

  • Targeting telomerase and telomeres presents a promising avenue for novel anticancer drug discovery.
  • Inhibitors of telomerase and telomeres can be studied using established in vitro and in vivo models.
  • Exploiting telomere biology offers a unique strategy to combat cancer.